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D cyclins positively regulate the cell cycle and mediate the pathogenesis of some lymphomas. Cyclin D1
overexpression is the hallmark of mantle cell lymphoma, whereas cyclins D2 and D3 are reportedly not as specific
to certain lymphomas as cyclin D1. In this study, cyclin D2 was found to be overexpressed in 98% of de novo
CD5-positive diffuse large B-cell lymphomas (DLBCLs) (50/51) and in 28% of CD5-negative DLBCLs (14/51). A
statistically significant difference was observed between these two groups (p<0.0001). In contrast, no statistical
difference was found in the cyclin D3 expression between CD5-positive (18/51) and CD5-negative (24/51) DLBCLs
(p=0.23). Based on these findings, cyclin D2 is therefore considered to be closely associated with de novo
CD5-positive DLBCLs. This insight may be useful for overcoming the inferior survival of this aggressive lymphoma.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1382856320966453
Keywords: Cyclin D2, CD5, Diffuse large B-cell lymphomaBackground
D-type cyclins (D1, D2, and D3) positively regulate the
cell cycle and mediate the pathogenesis of some
lymphomas [1]. The overexpresison of cyclin D1 due
to translocation t (11;14)(q13;q32) serves as a hallmark
for the diagnosis of mantle cell lymphoma [1]. Recently, a
rare type of cyclin D1-negative mantle cell lymphoma,
which overexpresses cyclins D2 or D3, was identified [2].
Cyclins D2 and D3 are also detected in various lymphomas,
but they have not been shown to be closely associated with
any particular subtype of lymphoma [3].
We recently demonstrated cyclin D2 to be overexpressed
in the proliferation centers of chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL) [4].
CLL/SLL is considered to be a disease caused by the
accumulation of CD5-positive B lymphocytes, and pro-
liferating tumor cells are located in the proliferation* Correspondence: satou-y@cc.okayama-u.ac.jp
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reproduction in any medium, provided the orcenters of lymph nodes [5]. The proliferating cells are
composed of paraimmunoblastic cells and most of them
are in the cell cycle, expressing Ki-67 antigen [5]. These
findings suggest that de novo CD5-positive diffuse large
B-cell lymphomas (CD5+ DLBCLs) share the characteristics
of actively proliferating cells in CLL/SLL.
De novo CD5+ DLBCLs account for approximately 10%
of all DLBCL cases, and they are characterized by a female
predominance, a higher age at diagnosis, and a high
degree of central nervous system relapse [6]. De novo CD5+
DLBCLs are also known to show a significantly poorer sur-
vival outcome than CD5-negative DLBCLs (CD5− DLBCLs)
under both cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) and rituximab-CHOP (R-CHOP)
therapy [6,7].
According to these previous data, we sought to clarify
the expression patterns of cyclins D2 and D3 in de novo
CD5+ DLBCLs.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Cyclins D2 and D3 expression in de novo CD5+
and CD5− DLBCLs
De novo CD5+DLBCLs CD5−DLBCLs P
Cyclin D2 50/51 (98%) 14/51 (28%) P < 0.0001
Cyclin D3 18/51 (35%) 24/51 (47%) P = 0.23
Table 2 Previous reports on cyclins D2 and D3 expression
by immunohistochemistry in DLBCLs
Reference (reference no.) No. of
patients
Cut-off
line (%)
Positive cases (%)
Cyclin D2 Cyclin D3
Hans CP, et al., 2004 [8] 152 30 13 ND
Hans CP, et al., 2005 [9] 200 30 19 62
Amen F, et al., 2007 [10] 80 10 25 ND
Metcalf RA, et al., 2010 [3] 194 20 49 20
Present study CD5+ DLBCLs 51 20 98 35
CD5− DLBCLs 51 20 28 47
ND, not done.
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Case selection
We studied 51 Japanese patients with de novo CD5+
DLBCLs diagnosed between 1998 and 2011 at Okayama
University, Tokai University, and Nagoya University. The
patients included 26 males and 25 females between 32
and 90 years of age (median age 68 years). The examined
tissue specimens were obtained from 32 lymph nodes
and 19 extranodal sites. The CD5 antigen expression
was examined by means of immunohistochemistry of
paraffin sections and/or flow cytometry. All samples
were immunohistochemically confirmed to be cyclin D1
and sox11 negative [2]. Any samples with a history of
other lymphoproliferative disorders were excluded from
the study.
As a control group, samples taken from 51 patients
with CD5− DLBCLs diagnosed between 1997 and 2011
at Okayama University were also examined. The patients
included 27 males and 24 females between 23 and 89 years
of age (median age 68 years). The examined tissue speci-
mens were obtained from 42 lymph nodes and 9
extranodal sites. In all cases, the CD5 antigen expression
was examined by both immunohistochemistry and flow
cytometry.Figure 1 Cyclins D2 and D3 expression in de novo CD5-positive and C
(A, B, and C) and CD5-negative (D, E, and F) DLBCLs, H&E staining (A & D),
D2 staining was frequently localized to both the nucleus and the cytoplasm
nuclear staining pattern in both CD5-positive and negative DLBCLs (C & F)Histological examination and immunohistochemistry
The tissue samples were fixed in 10% formalin and em-
bedded in paraffin. The sections (4-μm thick) were stained
with H&E. Immunohistochemistry was performed on the
paraffin-fixed sections using an automated Bond-max
stainer (Leica Biosystems, Melbourne, Australia) and
anti-cyclin D2 (polyclonal; 1:150; Proteintech Group
Inc., Chicago, IL, USA) and anti-cyclin D3 (DCS-22;
1:10; Progen Biotechnik GmbH, Heidelberg, Germany)
antibodies. Based on previous studies, a sample was consid-
ered to be positive if ≥20% of the tumor cells were stained
[3]. Faint cytoplasmic staining for cyclin D2 without corre-
sponding nuclear staining was not considered positive.
Statistical analysis
The correlations between the 2 groups were examined
by a chi-square analysis. All statistical analyses were carried
out with the SPSS software program (version 14.0, SPSS
Inc., Chicago, USA).D5-negative DLBCLs. Cyclin D2 expression in de novo CD5-positive
cyclin D2 staining (B & E), and cyclin D3 staining (C & F) (×400). Cyclin
in the de novo CD5-positive DLBCLs (B). Cyclin D3 showed a crisp
.
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In this study, our data showed that cyclin D2 was
overexpressed in 98% of de novo CD5+ DLBCLs (50/51)
and in 28% of CD5− DLBCLs (14/51) (Table 1, Figure 1).
A statistically significant difference was observed between
these two groups (p<0.0001). In contrast, no statistical
difference was found in the cyclin D3 expression between
CD5-positive (18/51) and CD5-negative (24/51) DLBCLs
(p=0.23) (Table 1, Figure 1). Since de novo CD5+ DLBCLs
are typically immunohistochemically negative for cyclin D1
[6], these findings therefore indicate that cyclin D2 is
closely associated with de novo CD5+ DLBCLs.
Previous studies have examined the cyclins D2 and D3
expression in DLBCLs by immunohistochemistry (Table 2)
[3,8-10]. Although the rates of cyclins D2 and D3 positive
cases were highly variable in these studies, our findings
suggest that cyclin D2-positive DLBCLs comprise the
majority of de novo CD5+ DLBCLs.
Several studies have shown cyclin D2 to be an inde-
pendent indicator of an inferior survival in DLBCLs
[8-10]. In addition, Lossos et al. identified CCND2 to be
the best predictor of an inferior survival in DLBCLs
among the 36 genes associated with their prognosis
based on quantitative RT-PCR [11]. These data suggest
that cyclin D2 may be associated with the inferior survival
observed in de novo CD5+ DLBCLs. The current gold
standard therapy has evolved to include rituximab, and the
outcome of DLBCLs has been reported to have dramatic-
ally improved [12]. However, both CCND2 and CD5 have
been demonstrated to still be a good indicator of the infe-
rior survival in DLBCLs, even in the era of R-CHOP [7,12].
This fact also suggests an association between cyclin D2
and the poor survival in de novo CD5+ DLBCLs. Similar to
de novo CD5+ DLBCLs, cyclin D2-positive CD5− DLBCLs
may play a role in the negative prognostic impact of cyclin
D2 in DLBCLs. In the current study, however, whether or
not cyclin D2-positive CD5−DLBCLs show a poor survival
was not examined. As a result, the prognostic impact of this
population therefore still needs to be investigated.
Conclusions
Cyclin D2 is closely associated with de novo CD5+ DLBCLs.
This insight might be useful for making treatment strategies
and improving the survival of this aggressive lymphoma,
since cyclin D2 expression is controlled by multiple signal-
ing pathways, such as the NFkB-related pathways [13].
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